Cargando…

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates

BACKGROUND: Protease inhibitor (PI)-resistant HIV-1 isolates with primary substitutions in protease (PR) and secondary substitutions in Gag could potentially exhibit cross-resistance to maturation inhibitors. We evaluated the second-generation maturation inhibitor, GSK3532795, for activity toward cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray, Neelanjana, Li, Tianbo, Lin, Zeyu, Protack, Tricia, van Ham, Petronella Maria, Hwang, Carey, Krystal, Mark, Nijhuis, Monique, Lataillade, Max, Dicker, Ira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JAIDS Journal of Acquired Immune Deficiency Syndromes 2017
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389583/ https://www.ncbi.nlm.nih.gov/pubmed/28234686 http://dx.doi.org/10.1097/QAI.0000000000001304

Ejemplares similares

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
por: Dicker, Ira, et al.
Publicado: (2019)

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
por: Hwang, Carey, et al.
Publicado: (2017)

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022)

Correction: Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
Publicado: (2019)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
por: Morales-Ramirez, Javier, et al.
Publicado: (2018)

Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors
por: Lin, Zeyu, et al.
Publicado: (2016)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
por: Nijhuis, Monique
Publicado: (2011)

Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage
por: Nowicka-Sans, Beata, et al.
Publicado: (2016)

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat
por: Fun, Axel, et al.
Publicado: (2011)

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
por: Zhang, Ying, et al.
Publicado: (2023)

The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors
por: Mahameed, Mohamed, et al.
Publicado: (2019)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
por: Wang, Chunfu, et al.
Publicado: (2023)

Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease
por: Lin, Yuxi, et al.
Publicado: (2021)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase
por: Berger, SB, et al.
Publicado: (2015)

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
por: Pospelov, Evgeny V., et al.
Publicado: (2020)

Scabies Mite Inactive Serine Proteases Are Potent Inhibitors of the Human Complement Lectin Pathway
por: Reynolds, Simone L., et al.
Publicado: (2014)

Cloning and Characterization of Two Potent Kunitz Type Protease Inhibitors from Echinococcus granulosus
por: Ranasinghe, Shiwanthi L., et al.
Publicado: (2015)

General and Modular Strategy for Designing Potent, Selective, and Pharmacologically Compliant Inhibitors of Rhomboid Proteases
por: Tichá, Anežka, et al.
Publicado: (2017)

Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
por: Joshi, Samit R., et al.
Publicado: (2020)

Pharmacophore feature-based virtual screening for finding potent GSK-3 inhibitors using molecular docking and dynamics simulations
por: Chauhan, Navneet, et al.
Publicado: (2016)

GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice
por: Pearce, Andrew C., et al.
Publicado: (2021)

Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library
por: Dawadi, Surendra, et al.
Publicado: (2020)

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
por: Shan, Hengyue, et al.
Publicado: (2021)

Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
por: Li, Lingyu, et al.
Publicado: (2022)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease
por: Cooper, Mark S., et al.
Publicado: (2022)

QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease
por: Song, Fucheng, et al.
Publicado: (2023)

SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
por: BATIBAY, Gönül S., et al.
Publicado: (2023)

GSK-3 inhibitors induce chromosome instability
por: Tighe, Anthony, et al.
Publicado: (2007)

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Viral Protease Inhibitors
por: Anderson, Jeffrey, et al.
Publicado: (2009)

Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity
por: van Maarseveen, Noortje M, et al.
Publicado: (2012)

Discovery of a novel Aurora B inhibitor GSK650394 with potent anticancer and anti-aspergillus fumigatus dual efficacies in vitro
por: He, Yuhua, et al.
Publicado: (2021)

In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease
por: Yañez, Osvaldo, et al.
Publicado: (2021)

A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo
por: Van Dycke, Jana, et al.
Publicado: (2021)

Discovery of 4′-O-methylscutellarein as a potent SARS-CoV-2 main protease inhibitor
por: Wu, Qianqian, et al.
Publicado: (2022)

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis
por: Oh, Hyeon Seok, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jo7c87956dejpjv2gml33fm8tv